Since 2019, the UK’s strong reputation in global health has been undermined by a series of cuts and a distracting departmental reorganisation. November 2023 may represent a turning point—with a new Foreign Minister who has historically championed aid as Prime Minister, and the publication of a new i...

Across the world, children are facing unacceptable levels of violence in schools. We need more and better data to understand this problem and find the best ways to eliminate violence in schools. But getting accurate measures of violence is not easy. When it comes to collecting data for children in s...

In recent decades, concerted efforts to promote access, equity, and inclusivity in education have improved school enrollment for girls and marginalized and disadvantaged populations. Kenya is no exception: it has reached gender parity at the primary school level, and the Kenyan government has implem...

Prior to the COVID-19 pandemic there were periods of sustained growth in many low- and middle-income countries that led to some optimism about countries “transitioning” from (i.e. no longer being eligible for) support from the major global health financing mechanisms, such as the Global Fund, Gavi, ...

The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...

Health systems in Africa are under considerable strain: rapid demographic change, rising non-communicable diseases, and emerging and re-emerging threats such as COVID-19 and Ebola are increasing demands on limited health services. The African Union’s admission to the G20 provides an opportunity for ...

Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...